NEUMORA THERAPEUTICS INC (NMRA) competitors & alternatives
Health Care · NASDAQ
NEUMORA THERAPEUTICS INC (NMRA)'s top competitors and alternatives — its most similar public companies — include Axsome Therapeutics, Inc. (AXSM), ACADIA PHARMACEUTICALS INC (ACAD), RAPPORT THERAPEUTICS INC (RAPP), MINERVA NEUROSCIENCES INC (NERV), PTC THERAPEUTICS INC (PTCT), DYNE THERAPEUTICS INC (DYN), BEAM THERAPEUTICS INC (BEAM), FOGHORN THERAPEUTICS INC (FHTX), PRELUDE THERAPEUTICS INC (PRLD), PERSPECTIVE THERAPEUTICS INC (CATX), BIODESIX INC (BDSX) and NAUTILUS BIOTECHNOLGY INC (NAUT). These are NEUMORA THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top NMRA competitors & alternatives
-
Axsome Therapeutics, Inc.AXSMHealth Care
A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel…
$239.62 (as of 2026-07-22) · market cap $12.3B
-
ACADIA PHARMACEUTICALS INCACADHealth Care
Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare…
$24.96 (as of 2026-07-22) · market cap $4.4B
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
MINERVA NEUROSCIENCES INCNERVHealth Care
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on…
$4.43 (as of 2026-07-22) · market cap $209M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
DYNE THERAPEUTICS INCDYNHealth Care
Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious,…
$23.21 (as of 2026-07-22) · market cap $3.8B
-
BEAM THERAPEUTICS INCBEAMHealth Care
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare…
$26.64 (as of 2026-07-22) · market cap $2.7B
-
FOGHORN THERAPEUTICS INCFHTXHealth Care
Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal…
$5.21 (as of 2026-07-22) · market cap $306M
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
PERSPECTIVE THERAPEUTICS INCCATXHealth Care
Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical…
$2.97 (as of 2026-07-22) · market cap $337M
-
BIODESIX INCBDSXHealth Care
Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and…
$21.39 (as of 2026-07-22) · market cap $222M
-
NAUTILUS BIOTECHNOLGY INCNAUTHealth Care
A pre-commercial proteomics platform company developing Iterative Mapping technology to enable single-molecule protein counting for comprehensive, reproducible…
$1.70 (as of 2026-07-22) · market cap $216M
Not quite? Describe exactly what you want →
Peers are NEUMORA THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: NEUMORA THERAPEUTICS INC (NMRA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.